Veracyte (United States)

Recent papers from Veracyte (United States)

1. Increasing cancer stemness drives prostate cancer progression, plasticity, therapy resistance and poor patient survivalMolecular Cancer · 2026
2. Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical TrialJournal of Clinical Oncology · 2026
3. Multi-institutional Patient-level Comparison of Decipher Genomic Classifier and Artera Multimodal Artificial Intelligence (MMAI) in Prostate CancerClinical Cancer Research · 2026
4. Distinct molecular profiles of indeterminate and malignant thyroid nodules in patients under 21 years of ageEndocrine Related Cancer · 2026
5. IRE1 activity is prognostic in localised and metastatic prostate cancer and affects epithelial lineage statesEMBO Molecular Medicine · 2026
6. Stress-mediated reactive oxygen species from mitochondria dysregulates the tumor microenvironment in prostate cancerScientific Reports · 2026
7. APUC-6 Genes as a Potential Prognostic and Predictive Biomarker in the CHAARTED Prostate Cancer TrialJCO Precision Oncology · 2026
8. Development of Novel mRNA Classifiers to Stratify Preoperative Thyroid Tumor RiskOtolaryngology · 2026
9. Genomic enrichment using Decipher and PAM50 luminal B to optimize neoadjuvant immunotherapy strategies in high-risk prostate cancer.Journal of Clinical Oncology · 2026
10. Assessing the clinical and biological associations between multimodal artificial intelligence (MMAI) and 22-gene genomic classifier (GC) in localized prostate cancer (PCa).Journal of Clinical Oncology · 2026
11. The Molecular Heterogeneity of NRAS Variants in Thyroid NodulesOtolaryngology · 2026
12. Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 TrialJournal of Clinical Oncology · 2026
13. Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study.Journal of Clinical Oncology · 2026
14. Clinico-transcriptomic risk stratification to guide abiraterone treatment intensification in high-risk prostate cancer: A combined analysis of NRG/RTOG 9202, 9413, 9902, and 0521.Journal of Clinical Oncology · 2026
15. Neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer: Final results and biomarker analyses of the SURE-01 trial.Journal of Clinical Oncology · 2026
16. Molecular characterization of residual disease post-neoadjuvant sacituzumab govitecan (SG), pembrolizumab, or their combination in patients with muscle-invasive bladder cancer (MIBC).Journal of Clinical Oncology · 2026
17. Practice patterns and outcomes by genomic risk in octogenarians with high-risk localized prostate cancer: A national real-world data analysis.Journal of Clinical Oncology · 2026
18. Characterizing the Activity of Inflammasome‐Related Genes and Their Association With Oncological Outcomes in Prostate CancerThe Prostate · 2026
19. High folate receptor expression is associated with aggressive features in prostate cancer with low prostate‐specific membrane antigen expressionBJUI Compass · 2026
20. B80-4-09 Clinical and Radiographic Differences Between Patients With Screening-Identified and Incidental Pulmonary Nodules: Results From a Multi-Center Prospective StudyAmerican Journal of Respiratory and Critical Care Medicine · 2026